<DOC>
	<DOCNO>NCT02362087</DOCNO>
	<brief_summary>The purpose study document course action physician choose patient develop taxane acute pain syndrome ( TAPS ) identify patient great risk TAPS examine specific human genome marker single nucleotide polymorphism ( SNPs ) Copy Number Variations ( CNVs ) may explain genetic ( hereditary ) component .</brief_summary>
	<brief_title>Taxane Acute Pain Syndrome ( TAPS ) Patients Receiving Taxane Chemotherapy Breast Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Diagnosed either invasive breast prostate cancer ( stage IIV ) Age ≥18 year ECOG performance status ≤2 Scheduled receive intravenous taxanebased chemotherapy either adjuvant metastatic disease Participants need ability complete questionnaire assistance ability provide inform write consent Concurrent use agent try prevent treat neuropathy TAPS , include gabapentin , glutamine , vitamin B6 , vitamin E. Preexisting history peripheral neuropathy great grade 1 NCI CTCAE version 4.0 cause ( chemotherapy , diabetes , alcohol , toxin , hereditary , etc . ) medical condition would make study participation unreasonably hazardous Uncontrolled diabetes Medical psychiatric illness would interfere patient ' ability complete diary</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pain</keyword>
</DOC>